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the remaining 15 were kidney recipients. Fifteen 
episodes in 13 patients were CMV gastritis and/or 
colitis, 4 were CMV syndrome without end-organ 
disease. Two end-organ involvement was seen in 
the remaining patient; CMV pneumonia nd coli- 
tis. Histopathological diagnosis was available for 
15 of the episodes along with CMV PCR or CMV 
pp65 antigenemia. The remaining 4 episodes were 
diagnosed with CMV PCR or CMV pp65 antigenemia. 
All patients were treated with intravenous gancy- 
clovir for 2-4 weeks. All patients responded to the 
therapy and survived. 
Conclusion: Major advances have been achieved 
regarding the management of CMV infection and 
disease. These advances have been made possible 
through the development of new techniques for 
the detection of the virus. CMV pp65 antigenemia 
testing or CMV PCR is useful for surveillance of 
active infection. As a result of prevention and 
treatment of CMV infection, both the direct and 
indirect effects secondary to CMV replication have 
led to improved outcomes. 
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Background: Cytomegalovirus (CMV) sero(-) recipi- 
ents of sero(+) donor organs (D+) are at high risk for 
CMV infection and disease and qualify for universal 
prophylaxis with oral ganciclovir (GCV) or valGCV. 
However, CMV D+R- patients have also an increased 
risk for GCV-resistant CMV disease as compared 
to CMV D+R+ patients, presumably due to lack of 
specific immune effectors, especially CMV-specific 
CD4+ and CDS+ T cells. 
Objectives: We investigated the CMV specific cel- 
lular immune response in seropositive recipients 
after ganciclovir treatment and after clinical CMV 
resistance. 
Methods: CMV specific interferon gamma (IFNy) 
production of CD4+ and CDS+ T cells were mea- 
sured after stimulation with viral protein (CMV 
lysat, pp72, pp65), negative and positive control 
(SEB) in the peripheral blood mononuclear cells 
(PBMC) using intracellular cytokine staining and 
flow cytometry. The frequency of the response was 
compared in 7 CMV-sero(+) and 9 sero(-) healthy 
controls and in kidney transplant recipients, 5 
sero(-) R-, and 11 sero(+)R+. CMV replication was 
measured by real-time PCR, CMV Ig by AxSym. 
Results: In R-, the frequency of CMV specific CD4+ 
and CDS+ T cells was <0.03% and <0.03%, similar to 
sero(-) healthy controls (p non significant). In R+, 
the mean frequency of CD4+ and CDS+ T cells was 
0.36% and 0.13% and higher than in R-, but signifi- 
cantly lower than in healthy controls (CD4+ 3.91%, 
CDS+ 2.27%, p<0.010). One R-D+//1 underwent pri- 
mary CMV infection and responded to intravenous 
GCV treatment. Despite of subsequent seroconver- 
sion, CD4+: 0.02% and CDS+: 0.01% remained low, 
and recurrence was observed (PCR 6xl03c/ml). 
No clinical or laboratory sign for treatment re- 
sistance as seen after retreatment with valGCV. 
R+D+//3 developed a CMV therapy resistance with 
low level viral production showed persisting CMV 
loads 1-5x104c/ml despite treatment with val- 
GCV, intravenous GCV, and eventual switching to 
leflunomide. CMV IgG were >250AU/ml, but CD4+ 
and CDS+ specific response remained low 0.07% and 
0.06%, respectively, over 12 months. 
Conclusions: Low CMV specific CD4+ and CDS+ 
T cell response may be associated with an in- 
creased risk for CMV resistance development in
CMV seropositive transplant patients with low or 
absent CMV specific CD4+ and CDS+ T cell re- 
sponses. An optimal use of testing cellular and hu- 
moral CDS+ CMV immunity before and after trans- 
plantation may be important o assess the risk of 
GCV resistance. 
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Objective: Chronic immunosuppression used in or- 
gan transplantation is associated with development 
of EBV-driven lymphoropliferative disease (PTLD) 
due to impairment of CDS+T cell surveillance. 
Pediatric heart transplant (HTx) patients are at 
higher risk, especially when they develop primary 
EBV infection after transplantation. Our goal was 
to characterize the immune responses to EBV in 
different cohorts of pediatric HTx patients. 
Methods: Thirty-five pediatric HTx patients were 
categorized according to EBV clinical history/viral 
load as follows: Group 1 (n=11) stable, no de- 
tectable viral load; Group 2 (n= 16) stable, low 
